Podcast Ep 29: Hypothyroidism and Myxedema Coma

Hypothyroidism management involves a complex interplay between the hypothalamus, pituitary gland, and thyroid, primarily treated with synthetic T4 (levothyroxine). While levothyroxine remains the gold standard, clinicians must navigate brand-name bioequivalence concerns and precise dosing, often based on ideal body weight, to avoid cardiovascular complications. Although T3 (liothyronine) is generally not recommended as monotherapy, it may benefit specific patients resistant to T4 or those experiencing persistent symptoms despite normalized hormone levels. Myxedema coma represents a critical endocrine emergency requiring aggressive IV T4 and glucocorticoid support, carrying significant mortality risks. Beyond thyroid disorders, recent pharmaceutical advancements include the approval of TPOX for smallpox, the HIV treatment Symptuza, and the epilepsy medication Epidiolex, reflecting rapid progress in specialized therapeutic areas.